top of page
EXELIXIS
Helping patients recover stronger and live longer
HCP + DTC
Eduardo Garza-Santos (AD) | Kieth Coney (AD) | Everett Aldrich (AD)
EXELIXIS develops therapies to treat different types of cancers. Our goal is to help them fill their clinical trials so they can test new therapies for FDA approval.
When COVID hit, the EXELIXIS team converted their conference booth into a 3D virtual replica online. I participated in the conversion from the virtual conference booth to a normal website to improve the user experience.
Here are a few pages of the site embedded in the page.
Social Posts - Twitter
Post Copy: 50% of patients enroll in clinical trials with a healthcare provider's recommendation. Tell your eligible patients with mCRPC about CONTACT-02.
Post copy: Clinical trial enrollment should reflect our diverse communities. See if the CONTACT-02 trial could be an option for your patients with metastatic castration-resistant prostate cancer.
Post copy: Your patients with mCRPC may be eligible for our CONTACT-02 trial. Learn more about eligibility criteria.
CONTACT-02 Clinical Trial Inclusivity Website Update
Certain cancers disproportionately affect Black/Brown populations, and the clinical trails testing potentially life-saving medicines do not reflect their own patient population. This underrepresentation needs to stop and EXELIXIS feels the same way. That's why we created DTC & HCP websites backed by stats, urging these two groups to talk about clinical trial treatment options.
Patient Support Emails
To support the launch of the HCP inclusivity website we created four emails packed with stats on both the impact of inequality and how doctors can influence change by bringing up enrollment opportunities with their patients
bottom of page